US Patent

US10829465 — Highly purified pharmaceutical grade tasimelteon

Composition of Matter · Assigned to Vanda Pharmaceuticals Inc · Expires 2035-02-12 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a process for preparing highly purified, pharmaceutical grade tasimelteon under Good Manufacturing Practices (GMP) conditions.

USPTO Abstract

A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.

Drugs covered by this patent

Patent Metadata

Patent number: US10829465
Jurisdiction: US
Classification: Composition of Matter
Expires: 2035-02-12
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.